---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-004251"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T14:57:14.762831+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Processa Pharmaceuticals prices $7M public offering of 1.56M shares and warrants at $4.50 per unit

## Summary
- Pricing of 1,555,555 shares (or pre-funded warrants) and common warrants at $4.50 per unit; gross proceeds ~$7M.
- Common warrants exercisable at $4.50/share, immediately exercisable, 5-year term; pre-funded warrants at $0.0001.
- H.C. Wainwright & Co. as sole placement agent with 7.0% cash fee and placement agent warrants.
- Offering closed Jan 30, 2024; net proceeds for general corporate purposes.
- 90-day lock-up on equity issuance subject to exceptions.

## SEC filing metadata
- accession: 0001493152-24-004251
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000149315224004251/0001493152-24-004251-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000149315224004251/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-004251
- JSON: https://secwatch.observer/filing/0001493152-24-004251.json
- Plain text: https://secwatch.observer/filing/0001493152-24-004251.txt

## Key facts
- Material Agreements
  Processa Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $7.0 million (effective 2024-01-26).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: approximately $7.0 million
  - Effective: 2024-01-26
  source text: On January 26, 2024, Processa Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell and issue, in a registered public offering (the “Offering”), (i) 476,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “common stock”), (ii) warrants to purchase 1,555,555 shares of common stock (the “Common Warrants”) and (iii) pre-funded warrants to purchase up to 1,079,555 shares of common stock in lieu of shares of common stock (the “Pre-Funded Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533743/000149315224004251/0001493152-24-004251-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.